Recent progress of albumin-based NO delivery systems includes: (1) pharmacokinetic characterization of SNO-BSA in mice [17]; (2) polyethylene glycol (PEG)-conjugated poly-SNO-BSA showing increased in vivo stability and prolonged release of NO [18]; (3) using human serum albumin (HSA) as the NO carrier and optimization of synthetic procedures [19–24]; and (4) a novel SNO HSA dimer being developed and evaluated as a potential anti-tumor drug [25]. Here, ALB is linked to neoplasm.